Swedish geneticist Svante Paabo won the 2022 Nobel Prize in Physiology or Medicine on Monday for discoveries that underpin our understanding of how modern day humans evolved from extinct ancestors.
If you are not happy with the results below please do another search
50 search results for:
LEO Pharma A/S, a global leader in medical dermatology, has launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD) – the most common form of eczema.
Moderna Inc. has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.
Arising out of Calcium’s DEI initiatives, the agency has launched the “I DON’T HAVE A BOX” campaign to drive awareness of the “race box” used in health data collection and its shortcomings in capturing true racial and ethnic diversity.
For emerging manufacturers, listing through all the steps of a launch plan can be intimidating, so hearing that medical affairs and communications needs to be integrated from the beginning can feel like one more thing is being added to the overflowing to-do list of an understaffed team.
Around two-thirds of adults in the United States do not plan to get updated COVID-19 booster shots soon, according to a survey conducted by the Kaiser Family Foundation (KFF), a health policy nonprofit organization.
The biopharma world – and markets – spent Thursday evening reacting as the FDA gave the green light to only its third-ever drug for ALS, Amylyx’s AMX0035.
Intercept Pharmaceuticals Inc. said on Friday its treatment for patients with advanced liver scarring due to non-alcoholic steatohepatitis (NASH) failed to meet the main goal of a late-stage study, sending its shares down as much as 21%.
As it gears up to launch several new products in the coming months, Moderna has created a new leadership role and onboarded an industry veteran, the company announced Thursday.
Two struggling Boston-based gene therapy companies – Solid Biosciences and AavantiBio – announced Friday they are merging to develop a portfolio of neuromuscular and cardiac programs, initially focusing on a lead candidate to treat Duchenne muscular dystrophy.